Table 3.
Predictive values for three markers used in pretreatment biopsy specimens for tumour regression grade and downstaging
| Patients with TRG 3–4 | P * | Patients with downstaged tumour (≤ ypT2) | P * | |
|---|---|---|---|---|
| Retrospective cohort | ||||
| CD133 (high versus low) | 1 of 21 (5) versus 32 of 74 (43) | 0·001 | 4 of 21 (19) versus 23 of 74 (31) | 0·281 |
| COX‐2 (high versus low) | 19 of 75 (25) versus 14 of 20 (70) | < 0·001 | 20 of 75 (27) versus 7 of 20 (35) | 0·463 |
| CD8+ TIL (high versus low) | 14 of 23 (61) versus 19 of 72 (26) | 0·003 | 12 of 23 (52) versus 15 of 72 (21) | 0·004 |
| Prospective cohort | ||||
| CD133 (high versus low) | 8 of 18 (44) versus 15 of 31 (48) | 0·790 | 5 of 18 (28) versus 14 of 31 (45) | 0·229 |
| COX‐2 (high versus low) | 12 of 34 (35) versus 11 of 15 (73) | 0·014 | 11 of 34 (32) versus 8 of 15 (53) | 0·165 |
| CD8+ TIL (high versus low) | 13 of 18 (72) versus 10 of 31 (32) | 0·007 | 10 of 18 (56) versus 9 of 31 (29) | 0·066 |
Values in parentheses are percentages. TRG, tumour regression grade; CD, cluster of differentiation; COX, cyclo‐oxygenase; TIL, tumour‐infiltrating lymphocyte.
*
χ2 or Fisher's exact test.